The Usefulness of Biotechnology Firms' Drug Development Status in the Evaluation of Research and Development Costs
- 1 January 2003
- journal article
- research article
- Published by SAGE Publications in Journal of Accounting, Auditing & Finance
- Vol. 18 (1) , 163-196
- https://doi.org/10.1177/0148558x0301800109
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Science and Technology as Predictors of Stock PerformanceCFA Magazine, 1999
- Revaluations of fixed assets and future firm performance: Evidence from the UKJournal of Accounting and Economics, 1999
- Accounting Standard-Setting Organizations and Earnings Relevance: Longitudinal Evidence from NYSE Common Stocks, 1927-93Journal of Accounting Research, 1999
- Have Financial Statements Lost Their Relevance?Journal of Accounting Research, 1999
- Intangible Assets and Stock Prices in the Pre-SEC EraJournal of Accounting Research, 1999
- Revalued Financial, Tangible, and Intangible Assets: Associations with Share Prices and Non-Market-Based Value EstimatesJournal of Accounting Research, 1998
- Changes in the value-relevance of earnings and book values over the past forty yearsJournal of Accounting and Economics, 1997
- Factors Influencing Firms' Disclosures about Environmental LiabilitiesReview of Accounting Studies, 1997
- The Effects of Cross‐Sectional Scale Differences on Regression Results in Empirical Accounting Research*Contemporary Accounting Research, 1996
- Regression DiagnosticsPublished by Wiley ,1980